Our History

PrecisemAb is committed to offering the safest antibody therapy for patients.

  Our Mission

Precision Antibodies, Maximum Specificity

PrecisemAb’s Universal Antibody Lock Technology ensures that antibodies are activated only at disease sites, improving targeting precision and reducing on-target, off-tumor toxicity. This results in safer and more effective treatments, especially for conditions where the same antigen is expressed in both tumors and healthy tissues.

We believe that medicine must be both effective and safe. Our mission is to develop antibody therapies that patients can trust throughout their treatment journey.

Health matters. PrecisemAb is dedicated to creating the safest antibody solutions possible—and the Universal Antibody Lock is just the beginning.

History

PrecisemAb is established by Professor Tien-Lu Cheng, Dr. YunChi Lu, Dr. YiAn Cheng and Professor Cheng's lab members.

 

Professor Cheng has cultivated in antibody engineering for 25 years and his original ‘‘Universal Antibody Lock’’ technology can effectively enhance antibody’s selectivity for diseases and reduce adverse effects caused by antibody drugs. This innovative technology represents a revolutionary breakthrough in biotechnology industry.

 

Keeping the ideal of ‘‘giving back to society with self professions’’ in mind, PrecisemAb is committed to creating the safest antibody treatment for patients.

Milestones

Universal Antibody Lock invented

National Innovation Award
– 2nd place in student group

MOST–FITI  Program
– Outstanding Entrepreneurship Award

National Invention and Creation Award  
– Silver Award
 
Selected as Meet Taipei Exhibitor

–PrecisemAb officially established
–National Startup Competition: Champion in business incubation group
–Join DCB Taiwan Phoenix Accelerator
–Join MOST Taiwan  Germination Program
–Future Tech Award winner

–Complete technology transfer agreement with Kaohsiung Medical University
–Complete seed round of fundraising
–Got selected as one out of fourteen exhibitors in Taiwan pavillion, BIO US.
–Top 2 Asian region candidates of StartUp Stadium pitch contest held by BIO US.

–Awarded the Ministry of Economic Affairs Startup Value Creation Program(SVCP)
–Received a patent in Singapore for the Antibody Lock platform technology.
–Completed a three-month training at SkyDeck (a renowned accelerator in the United States. 

–Participated in Taiwan Demo Day in Silicon Valley, winning the "Best Pitch Award" and the "Most Market Potential Award."
–Joined the Taiwan-Berkeley Health Innovation Accelerator at the University of California, Berkeley.
–Collaborated with GlycoNex Inc. to develop the novel glycoantibody GNX201.
–Participated in the Bio International Convention in North America. 

Our Values

Science

With a scientific spirit, we continuously reflect, experiment, analyze, and innovate to provide the most reliable solutions.

Innovation & Impact

We challenge problems and create impact through innovative scientific approaches, striving to improve human life.Our pursuit is not only technological advancement but also positive impact on the world.

Share & Teamwork

Diverse team members are our greatest asset, and we believe that innovation comes from diversity. Therefore, we are passionate about knowledge sharing and cross-disciplinary teamwork, driving scientific advancement together.
TOP